Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other targeting the mTOR signaling pathway with a drug called temsirolimus.
Sandra Horning
Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine,
Post a comment